Study finds that COVID-19 can cause long term alterations on corneal endothelial cells

News
Article

Specular microscopy showed that the ocular symptoms in the patients who had had COVID-19 included conjunctival hyperemia, foreign body sensation, tearing, ocular secretion, and chemosis.

Woman rubbing both her eyes Image credit: AdobeStock/Parkin

Image credit: AdobeStock/Parkin

A team of Turkish investigators lead by Oğuzhan Kılıçarslan, FEBO, FICO, MD, reported that COVID-19 affected the corneal endothelial cell morphology in patients with ocular symptoms.1 Kılıçarslan is from the Department of Ophthalmology, Ayancık State Hospital, Sinop, Turkey.

They conducted a study in which they investigated the long-term effects of the virus on corneal endothelial cell morphology in patients with ocular symptoms to assess possible corneal involvement in patients who recovered from the disease.

The study was comprised of 2 groups, the COVID-19 group of patients who had been diagnosed and treated at Istanbul University Cerrahpasa Medical Faculty with confirmed SARS-CoV-2 infection and ocular irritation symptoms and the control group with no ocular pathologies that included age- and sex-matched individuals.

The investigators performed noncontact specular microscopy using the center method 156 days after COVID-19 had been diagnosed to analyze the endothelial cell density (ECD), hexagonality (HEX), coefficient of variation, and central corneal thickness.

Microscopy results

A total of 54 patients who had COVID-19 and had ocular irritation and 72 controls were included.

Specular microscopy showed that the ocular symptoms in the patients who had had COVID-19 included conjunctival hyperemia, foreign body sensation, tearing, ocular secretion, and chemosis. The mean ECDs were 2,770 cells/mm2 in the COVID-19 group and 2,897 cells/mm2 in the control group; the mean HEX was 46.52 in the COVID-19 group and 58.22 ± 13.94 in the control group.

The patients who had had COVID-19 had significantly lower endothelial ECD and HEX levels than controls (p = 0.003 and p< 0.001, respectively).

Kılıçarslan and colleagues concluded, “COVID-19 can cause long-term alterations in the corneal endothelial cells, leading to decreased ECD and HEX. Future research should focus on the long-term implications of COVID-19 on the corneal health and visual outcomes.”

Reference:
  1. Kılıçarslan O, Yılmaz Çebi A, Doğan C, Arslan OS. Long-term corneal endothelial parameters of covid-19 patients with ocular surface symptoms. Cornea 2024;43:1124-1127; DOI: 10.1097/ICO.0000000000003552
Recent Videos
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
Dr. Nate Lighthizer shares key takeaways from the SECO Showcase on anterior segment technology and full laser certification course offered at SECO.
Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.
Three EnVision Summit faculty members weigh in on the importance of comanagement in glaucoma management, where artificial intelligence will lead eye care, and what hopes are on the horizon for corneal ectasia treatments.
Yvonne Ou, MD, outlined lifestyle modifications for glaucoma management that have proven beneficial, including yoga and cycling.
Robert L. Stamper, MD, weighs in on what he think more optometrists should know about glaucoma and current misconceptions concerning glaucoma testing.
© 2025 MJH Life Sciences

All rights reserved.